Resumen

GOMES, Marta  y  PRINCIPE, Fernando. Diffuse large B-cell lymphoma: Biological prognostic factors and treatment with anti-cd20 antibody. Arq Med [online]. 2014, vol.28, n.4, pp.104-112. ISSN 2183-2447.

Despite great progress has been made in diffuse large B-cell lymphoma treatment, especially with the combination of the anti-CD20 antibody (rituximab) with the standard chemotherapy, this disease’s clinical and biological heterogeneity is responsible for unpredictable responses to treatment and difficult prognostic assessment. The biological prognostication of these patients has been a target of incessant investigation, and several markers emerged as survival predictors in rituximab’s era. However, the methods and expression cut-offs used varied between studies, creating inconsistencies in the obtained results. The identification of reliable and easily assessed prognostic biomarkers is extremely important, because it will allow creation of new target therapies and individualization of treatment regimens.

Palabras clave : lymphoma; large b-cell; diffuse; prognosis; biological markers; biological therapy.

        · resumen en Portugués     · texto en Inglés     · Inglés ( pdf )